MedTrace Logo

Add-on Sodium Nitroprusside to Treatment as Usual in Schizophrenia

NCT01548612 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-03-08

No results posted yet for this study

Summary

In spite of the numerous studies on schizophrenia, its etiology and physiopathology remain unknown. Evidence suggests a possible implication of nitric oxide (NO) in schizophrenia. NO is a gas with unique chemistry and influences the release of neurotransmitters, learning, memory and neurodevelopment. Recent studies that investigated the role of NO in patients with schizophrenia found evidence that points to a disruption in NO-mediated neurotransmission in schizophrenia. Accordingly, we believe that the administration of sodium nitroprusside, an NO donor, will ameliorate schizophrenia symptoms.

Conditions

Interventions

DRUG

Sodium nitroprusside

Intravenous infusion of 0,5 mcg/kg/min for 240 minutes

DRUG

Glucose solution

Intravenous infusion of glucose solution 5% for 240 minutes

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Jaime EC Hallak, Doctor · Ribeirao Preto Medical School, University of Sao Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2009-06-30
Completion
2010-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01548612 on ClinicalTrials.gov